c-Myb Antibody (MYB286), Novus Biologicals™

c-Myb

Western Blot 0.5-1ug/ml, Flow Cytometry 0.5-1ug/million cells, Immunocytochemistry/Immunofluorescence 1-2ug/ml, Immunoprecipitation 0.5-1ug/500ug protein lysate

Monoclonal

Purified

RUO

Human

P10242

4602

A synthetic peptide, corresponding to aa 119-135 (RRKVEQEGYPQESSKAG) of c-myb oncoprotein, coupled to KLH

Primary

Store at 4C.

75 kDa

MYB286

Western Blot, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunoprecipitation

Unconjugated

Mouse

Cancer, Phospho Specific

PBS with 0.05% BSA. with 0.05% Sodium Azide

c-myb, Cmyb, c-myb protein (140 AA), c-myb_CDS, c-myb10A_CDS, c-myb13A_CDS, c-myb14A_CDS, c-myb8B_CDS, efg, Proto-oncogene c-Myb, transcriptional activator Myb, v-myb avian myeloblastosis viral oncogene homolog, v-myb myeloblastosis viral oncogene homolog (avian)

MYB

IgG1 κ

Protein A purified

The highly leukemogenic avian retrovirus E26 contains two oncogenes, v-Myb and v-Ets, which are expressed together as a fusion protein. The cellular homolog of v-Myb, designated c-Myb, encodes a transcription factor. Deletion or disruption of a negative regulatory domain mapping within the carboxy-terminal domain of c-Myb results in enhanced transactivating capacity and in parallel, leads to activation of its ability to transform hemopoietic cells. c-Myb is expressed preferentially, but not exclusively, in immature hemopoietic cells and its expression decreases as cells differentiate.